{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T16:34:19Z","timestamp":1792946059570,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jacadv.2026.103372","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:00:04Z","timestamp":1792789204000},"page":"103372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Trends in Oral Anticoagulant Prescribing for Atrial Fibrillation and Active Cancer in UK Primary Care"],"prefix":"10.1016","volume":"5","author":[{"given":"Joseph Junior","family":"Damba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Beradid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-3556","authenticated-orcid":false,"given":"Laurent","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8049-6875","authenticated-orcid":false,"given":"James M.","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Renoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jacadv.2026.103372_bib1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.jacadv.2026.103372_bib2","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.jacadv.2026.103372_bib3","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s41440-024-01660-4","article-title":"Risk of cancer history in cardiovascular disease among individuals with hypertension","volume":"47","author":"Suzuki","year":"2024","journal-title":"Hypertension Research"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103372_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaccao.2021.03.006","article-title":"Risk of atrial fibrillation according to cancer type: a nationwide population-based study","volume":"3","author":"Yun","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10.1016\/j.jacadv.2026.103372_bib5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/jamacardio.2016.0280","article-title":"Risk of malignant cancer among women with new-onset atrial fibrillation","volume":"1","author":"Conen","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.jacadv.2026.103372_bib6","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamacardio.2016.0582","article-title":"Association of atrial fibrillation and cancer","volume":"1","author":"Rahman","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"19","key":"10.1016\/j.jacadv.2026.103372_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029423","article-title":"Common cancer types and risk of stroke and bleeding in patients with nonvalvular atrial fibrillation: a population-based study in England","volume":"12","author":"Ajabnoor","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.jacadv.2026.103372_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104560","article-title":"Risk of ischemic stroke and major bleeding in patients with atrial fibrillation and cancer","volume":"29","author":"Aspberg","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"12","key":"10.1016\/j.jacadv.2026.103372_bib9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jacadv.2026.103372_bib10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jacadv.2026.103372_bib11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacadv.2026.103372_bib12","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"717","key":"10.1016\/j.jacadv.2026.103372_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3399\/bjgp22X719069","article-title":"Atrial fibrillation: NICE 2021 update and the focus on anticoagulation","volume":"72","author":"Jones","year":"2022","journal-title":"Br J Gen Pract"},{"issue":"36","key":"10.1016\/j.jacadv.2026.103372_bib14","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jacadv.2026.103372_bib15","first-page":"1847","article-title":"The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society Comprehensive guidelines for the management of atrial fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.jacadv.2026.103372_bib16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaccao.2020.09.008","article-title":"Patterns of anticoagulation use in patients with cancer with atrial fibrillation and\/or atrial flutter","volume":"2","author":"Fradley","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10.1016\/j.jacadv.2026.103372_bib17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/phar.2679","article-title":"Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010-2016","volume":"42","author":"Ardeshirrouhanifard","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.jacadv.2026.103372_bib19","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative effectiveness and safety between Apixaban, Dabigatran, Edoxaban, and rivaroxaban among patients with atrial fibrillation : a multinational population-based cohort study","volume":"175","author":"Lau","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacadv.2026.103372_bib20","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/STROKEAHA.123.045098","article-title":"Effectiveness and safety of edoxaban compared with Apixaban in elderly patients with nonvalvular atrial fibrillation: a real-world population-based cohort study","volume":"55","author":"Chiv","year":"2024","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.jacadv.2026.103372_bib21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaccao.2021.06.004","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer","volume":"3","author":"Deitelzweig","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"9","key":"10.1016\/j.jacadv.2026.103372_bib22","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/bcp.13299","article-title":"Trends in the prescription of novel oral anticoagulants in UK primary care","volume":"83","author":"Loo","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jacadv.2026.103372_bib23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"6","key":"10.1016\/j.jacadv.2026.103372_bib24","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103372_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","article-title":"Validation and validity of diagnoses in the General Practice Research Database: a systematic review","volume":"69","author":"Herrett","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacadv.2026.103372_bib27","doi-asserted-by":"crossref","DOI":"10.21037\/ace-22-4","article-title":"Quality and completeness of malignant cancer recording in United Kingdom Clinical Practice Research Datalink Aurum compared to hospital episode statistics","volume":"6","author":"Hagberg","year":"2022","journal-title":"Ann Cancer Epidemiol"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103372_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.jacadv.2026.103372_bib30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.jacadv.2026.103372_bib31","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.35152","article-title":"Oral anticoagulant prescribing among patients with cancer and atrial fibrillation in England, 2009-2019","volume":"130","author":"Ajabnoor","year":"2024","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jacadv.2026.103372_bib32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacadv.2026.103372_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejim.2018.10.012","article-title":"Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality","volume":"59","author":"Malavasi","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacadv.2026.103372_bib34","series-title":"Atrial Fibrillation: The Management of Atrial Fibrillation","year":"2014"},{"issue":"12","key":"10.1016\/j.jacadv.2026.103372_bib35","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/STR.0000000000000046","article-title":"Guidelines for the primary prevention of stroke","volume":"45","author":"Meschia","year":"2014","journal-title":"Stroke"},{"issue":"38","key":"10.1016\/j.jacadv.2026.103372_bib36","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur H J"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103372_bib39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12913-020-5058-1","article-title":"Trends in anticoagulant prescribing: a review of local policies in English primary care","volume":"20","author":"Ho","year":"2020","journal-title":"BMC Health Services Research"},{"key":"10.1016\/j.jacadv.2026.103372_bib40","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1136\/bmj.p2567","article-title":"NHS England drive sees almost half a million people started on anticoagulant drugs","volume":"383","author":"Mahase","year":"2023","journal-title":"Bmj"},{"key":"10.1016\/j.jacadv.2026.103372_bib42","series-title":"Notice. Basic & Clinical Pharmacology, 15e.","author":"Katzung","year":"2021"},{"issue":"9","key":"10.1016\/j.jacadv.2026.103372_bib43","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.18632\/aging.101931","article-title":"Aging and ischemic stroke","volume":"11","author":"Yousufuddin","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"15","key":"10.1016\/j.jacadv.2026.103372_bib44","doi-asserted-by":"crossref","first-page":"358","DOI":"10.21037\/atm.2019.04.91","article-title":"Management of hemoptysis in patients with lung cancer","volume":"7","author":"Gershman","year":"2019","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103372_bib45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.21037\/apm.2017.11.01","article-title":"Bleeding in cancer patients and its treatment: a review","volume":"7","author":"Johnstone","year":"2017","journal-title":"Annals of Palliative Medicine"},{"issue":"3","key":"10.1016\/j.jacadv.2026.103372_bib46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaccao.2021.07.003","article-title":"Direct oral anticoagulants in patients with cancer and nonvalvular atrial fibrillation","volume":"3","author":"Davis","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103372_bib47","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.24325","article-title":"Association between incident cancer and subsequent stroke","volume":"77","author":"Navi","year":"2015","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.jacadv.2026.103372_bib48","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacadv.2026.103372_bib49","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1161\/STR.0000000000000517","article-title":"Classification and management of ischemic stroke in patients with active cancer: a scientific statement from the American Heart Association","volume":"57","author":"Navi","year":"2026","journal-title":"Stroke"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26007945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26007945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T15:48:56Z","timestamp":1792943336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26007945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2772963X26007945"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103372","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in Oral Anticoagulant Prescribing for Atrial Fibrillation and Active Cancer in UK Primary Care","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103372"}}